First patient enrolled in PNOC035 trial for recurrent ATRT

The PNOC Foundation says the first patient has enrolled in PNOC035, a new adaptive clinical trial for children, adolescents and young adults with recurrent or progressive ATRT. The study is designed to test multiple therapies in one platform and could expand treatment options for one of the deadliest pediatric brain tumors.

Why it matters: - Recurrent ATRT has had very limited treatment options, leaving a major gap for patients whose tumors return after initial therapy. - PNOC035 is designed to speed up testing of new therapies and combinations for one of the most aggressive pediatric brain tumors. - The trial adds a new research pathway for children, adolescents and young adults ages 1 to 39.

What happened: - The PNOC Foundation announced the launch of PNOC035, a clinical trial for recurrent or progressive atypical teratoid rhabdoid tumor. - The first patient enrolled at UCSF Benioff Children’s Hospital this past week. - The trial was developed by the Pediatric Neuro-Oncology Consortium ATRT Working Group.

The details: - PNOC035 is a platform clinical trial, not a single-therapy study. - The design allows researchers to test multiple promising therapies within one shared infrastructure. - The trial can incorporate new treatment strategies as laboratory and clinical findings evolve. - PNOC says the study will use its global network of more than 300 researchers across 43 children’s hospitals on six continents. - PNOC has launched more than 30 clinical trials and has contributed to two FDA-approved therapies for pediatric brain tumors. - Additional PNOC institutions are expected to open enrollment in the coming months. - The trial is open to eligible patients ages 1 to 39.

Between the lines: - The adaptive platform model reflects a shift away from traditional one-drug-at-a-time pediatric trials. - That structure could make it easier to evaluate safety, effectiveness and benefit as new science emerges. - PNOC leaders framed the launch as a collaboration-driven effort powered by families, researchers, clinicians, donors and industry partners. - The trial launch also underscores how international consortia are becoming more central to rare pediatric cancer research.

What’s next: - More PNOC sites are expected to begin enrolling patients over the next several months. - The trial will continue adding and assessing therapies as new data emerge. - PNOC and its supporters say the long-term goal is to improve outcomes for children with ATRT and other brain cancers.

The bottom line: - PNOC035 is a notable step forward for recurrent ATRT research because it combines first-patient enrollment with a flexible trial design built to keep pace with new discoveries. - More information is available in the PNOC Foundation announcement.